Oncology Xagena
A study suggests that Aranesp ( Darbepoetin alfa ) administered every three weeks with intravenous ( IV ) iron has the potential to further enhance the effectiveness of increasing patient hemoglobin ...
A study suggests that Aranesp ( Darbepoetin alfa ) administered every three weeks with intravenous ( IV ) iron has the potential to further enhance the effectiveness of increasing patient hemoglobin ...
Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" ( ESAs ) to treat anemia in so ...
In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent ( ESA ) Epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulti ...
